A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa

Inclusion Criteria:

1. Signs and symptoms of hidradenitis suppurativa (HS) for at least 6 months prior toScreening.

2. At least 5 inflammatory lesions in at least 2 distinct anatomical areas, at least 1of which is Hurley Stage 2 or 3.

Exclusion Criteria:

1. Has a draining fistula count of ≥ 20.

2. Has another active skin inflammatory condition, infection (viral, bacterial, orfungal), or another active ongoing inflammatory disease (other than HS) thatrequires treatment with a prohibited medication, which could interfere with theassessment of HS.

3. History of chronic or recurrent infectious disease, including but not limited tochronic renal infection, chronic lung infection, recurrent urinary tract infection,or open, draining or infected skin wounds or ulcers (not related to HS).

4. Has severe, progressive and/or uncontrolled renal, hepatic, hematologic, endocrine,pulmonary, cardiac, neurologic or immunosuppressive disease.